文献速递消化道出血消化内镜

计划性二次内镜检查对消化性溃疡出血的影响:一项前瞻性随机多中心试验

Effect of scheduled second-look endoscopy on peptic ulcer bleeding: a prospective randomized multicenter trial.
PubMed 文献 · Gastrointest Endosc · 2017-07-20

这项前瞻性随机多中心试验将319例内镜下确诊的出血性消化性溃疡患者随机分组,比较计划性二次内镜与单次内镜的疗效。结果显示两组再出血率无显著差异(10.1% vs 5.6%,P=.132),结论为单次内镜不劣于计划性二次内镜。

要点

  • 计划性二次内镜组再出血率10.1%,单次内镜组5.6%,差异无统计学意义(P=.132)。
  • 两组手术干预、放射介入、住院时间、输血量和死亡率均无显著差异。
  • 内镜医师评估止血成功度为3-4级、NSAID使用史和输血≥4单位红细胞是再出血独立危险因素。

核心结论

  • 单次内镜止血在降低消化性溃疡出血再出血率方面不劣于计划性二次内镜。
  • 对初始内镜止血不满意、使用NSAIDs和输血量较大的患者,重复内镜可能有帮助。

研究设计与样本

  • 前瞻性随机多中心试验,2010年8月至2013年1月纳入319例内镜下确诊的出血性消化性溃疡患者,伴有活动性出血、可见血管或附着血凝块的征象。

主要发现

  • 计划性二次内镜组再出血16例(10.1%),单次内镜组9例(5.6%),P=.132。
  • 手术干预:计划性二次内镜组0例(0%),单次内镜组1例(0.6%),P>.999。
  • 放射介入:计划性二次内镜组3例(1.9%),单次内镜组2例(1.2%),P=.683。
  • 中位住院时间:计划性二次内镜组6.0天,单次内镜组5.0天,P=.151。
  • 输血量:计划性二次内镜组2.4±1.7单位,单次内镜组2.2±1.6单位,P=.276;死亡率:计划性二次内镜组2例(1.3%),单次内镜组2例(1.2%),P>.999。

关键数值与推荐

  • 初始内镜治疗允许使用止血夹或热凝和/或肾上腺素注射,并静脉注射相同剂量的质子泵抑制剂。
  • 研究组在初始止血后24至36小时接受计划性二次内镜,如内镜征象持续则追加治疗。
  • 再出血患者尽管接受额外内镜治疗仍进行手术或放射介入。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: This study aimed to investigate the effectiveness of scheduled second-look endoscopy (EGD) with endoscopic hemostasis on peptic ulcer rebleeding and to identify the risk factors related to the need for second-look EGD. METHODS: We prospectively randomized patients who had endoscopically confirmed bleeding peptic ulcer with stigmata of active bleeding, visible vessel, or adherent clot into 2 groups between August 2010 and January 2013. Hemoclip application or thermal coagulation and/or epinephrine injection were allowed for initial endoscopic therapy. The same dosage of proton pump inhibitor was injected intravenously. The study group received scheduled second-look EGD 24 to 36 hours after the initial hemostasis, and further therapy was applied if endoscopic stigmata persisted, as above. Those patients who developed rebleeding underwent operation or radiologic intervention despite the additional endoscopic therapy. Outcome measures included rebleeding, amount of transfusion, duration of hospitalization, and mortality. RESULTS: After initial endoscopic hemostasis, 319 eligible patients were randomized into 2 groups. Sixteen (10.1%) and 9 (5.6%) patients developed rebleeding (P = .132), respectively. There was also no difference in surgical intervention (0, 0% vs 1, .6%, P >.999) or radiologic intervention (3, 1.9% vs 2, 1.2%, P = .683), median duration of hospitalization (6.0 vs 5.0 days, P = .151), amount of transfusion (2.4 ± 1.7 vs 2.2 ± 1.6 units, P = .276), and mortality (2, 1.3% vs 2, 1.2%, P > .999) between the 2 groups. Multivariate analysis showed that grades 3 to 4 of endoscopists' estimation to success of initial hemostasis, history of nonsteroidal anti-inflammatory drug (NSAID) use, and larger amounts of blood transfusions (≥4 units of red blood cells) were the independent risk factors of rebleeding. CONCLUSIONS: A single EGD with endoscopic hemostasis is not inferior to scheduled second-look endoscopy in terms of reduction in rebleeding rate of peptic ulcer bleeding. Repeat endoscopy would be helpful in the patients with unsatisfactory initial endoscopic hemostasis, use of NSAIDs, and larger amounts of transfused blood. (Clinical trial registration number: KCT0000565; 4-2010-0348.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Park SJ, Park H, Lee YC, et al. Effect of scheduled second-look endoscopy on peptic ulcer bleeding: a prospective randomized multicenter trial. Gastrointest Endosc. 2017. PMID: 28735835. doi:10.1016/j.gie.2017.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。